TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER).
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
| Metabolism | Metabolized via amino acid oxidation and gluconeogenesis in the liver and kidneys. Dextrose undergoes glycolysis and oxidative phosphorylation. Electrolytes are not metabolized but excreted or retained as needed. |
| Excretion | Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible. |
| Half-life | Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary. |
| Protein binding | None for components. Amino acids: minimal (<10%). |
| Volume of Distribution | Not applicable as a mixture; individual components distribute into total body water (0.6 L/kg) or extracellular fluid (0.2 L/kg). |
| Bioavailability | Intravenous: 100% (only route). |
| Onset of Action | Intravenous: immediate (within minutes) for caloric and electrolyte effects. |
| Duration of Action | Intravenous: caloric effect persists while infused; rapid decline post-infusion. Clinical effect: continuous during administration. |
| Molecular Weight | Average molecular weight of amino acids in solution: ~130 Da per amino acid (range 75-204 Da). Dextrose: 180.16 Da. Electrolytes: ions. Overall mixture not a single molecular entity. |
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 mL/min, adjusted to meet metabolic requirements.
| Dosage form | INJECTABLE |
| Renal impairment | In renal impairment (GFR <30 mL/min): restrict fluid and electrolytes; use specialized amino acid formulations (e.g., essential amino acid solutions). Dextrose content may cause hyperglycemia; monitor glucose. Reduce volume and electrolytes as needed. For non-dialysis patients, avoid unless specific benefits outweigh risks. |
| Liver impairment | In hepatic impairment (Child-Pugh class B or C): monitor for encephalopathy; amino acid load may precipitate hepatic encephalopathy. Use lower protein intake (0.6-0.8 g/kg/day) or branched-chain amino acid enriched solutions. Dextrose may exacerbate hyperglycemia; adjust insulin as needed. |
| Pediatric use | Weight-based: neonates 1-3 g/kg/day amino acids, up to 15 g/kg/day dextrose, titrated. Infants and children: 1-2 g/kg/day amino acids, 10-20% dextrose at 1-2 mL/kg/hour. Adjust electrolytes per serum levels. Use age-specific formulations; monitor growth and metabolic parameters. |
| Geriatric use | Elderly: start at lower volume (0.5-1 L/day) due to reduced renal function and fluid reserve. Monitor glucose and electrolytes closely; dextrose load may require insulin. Amino acid dosing per protein requirements (1-1.2 g/kg/day if no renal impairment). Adjust for comorbidities. |
| 1st trimester | TRAVASOL is a parenteral nutrition solution providing amino acids, electrolytes, and dextrose. No adequate well-controlled studies in pregnant women. Use only if clearly needed. Dextrose component may affect maternal glucose levels; monitor closely. |
| 2nd trimester | Generally considered safe when used for nutritional support in pregnant women with protein-energy malnutrition. Monitor electrolytes and glucose. Avoid hyperglycemia. |
| 3rd trimester | Use with caution: potential for fluid and electrolyte imbalances, hyperglycemia, or volume overload. Monitor maternal and fetal well-being. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER).
| Placental transfer | Amino acids, electrolytes, and dextrose are normally present in maternal blood and cross the placenta via active transport and diffusion. No specific data for this formulation; expect placental transfer of all components. |
| Breastfeeding | Excretion in human milk unknown. Since components are endogenous substances normally present in breast milk, use with caution. Consider benefit of maternal nutrition versus potential risk to infant. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if clearly needed. Potential fetal risks include metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) associated with maternal administration of dextrose and electrolytes, which may affect fetal homeostasis. However, no specific teratogenic effects have been documented. |
| Fetal Monitoring | Monitor maternal blood glucose, serum electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate), serum osmolarity, acid-base balance, and fluid status. Assess for signs of hyperglycemia, electrolyte disturbances, and fluid overload. Fetal monitoring may be indicated in cases of maternal metabolic instability. |
| Fertility Effects | Effects on fertility have not been studied. No specific data available regarding impact on male or female fertility. The underlying condition requiring parenteral nutrition may influence fertility. |
■ FDA Black Box Warning
Not for intravenous injection as a sole source of nutrition. Contains aluminum that may be toxic. Use with caution in renal impairment due to aluminum accumulation. Do not administer unless solution is clear and container undamaged.
| Serious Effects |
Hypersensitivity to any componentSevere electrolyte disorders (e.g., hyperkalemia, hypernatremia) before correctionSevere metabolic acidosisHepatic coma or severe hepatic insufficiencySevere renal impairment (oliguria, anuria) not on dialysisHyperglycemia >300 mg/dL uncontrolledIntracranial or intraspinal hemorrhage (dextrose-containing solutions)
| Precautions | Risk of hyperglycemia, especially in diabetic patients, Electrolyte imbalances (hyperkalemia, hypophosphatemia, etc.), Volume overload in patients with heart failure or renal disease, Aluminum toxicity with prolonged use, especially in renal impairment, Thrombophlebitis and infection at infusion site, Refeeding syndrome in malnourished patients |
| Food/Dietary | None; parenteral nutrition bypasses gastrointestinal tract. However, monitor oral intake if transitioning to enteral nutrition. |
| Clinical Pearls | Contains 2.75% amino acids, 15% dextrose, and electrolytes. Ensure central line access for high osmolality (approx. 1450 mOsm/L). Monitor serum electrolytes, glucose, and fluid status. Avoid in patients with severe metabolic alkalosis or anuria. Contains sulfite, may cause allergic reactions in asthmatics. |
| Patient Advice | This solution provides nutrition and fluids directly into your vein. · Your blood sugar and electrolyte levels will be monitored regularly. · Report any signs of infection at the IV site like redness, swelling, or warmth. · Do not stop or adjust the infusion rate yourself. |
Loading safety data…